Difference between revisions of "Sebastian M, et al. Cancer Immunol. Immunother. (2007) cited as Ref 561 in DOI: 10.1038/s41392-020-0110-5 (Q9824)"
Jump to navigation
Jump to search
(Created claim: Volume (P103): 56, #quickstatements; #temporary_batch_1590009084631) |
(Created claim: title (P93): Treatment of non-small cell lung cancer patients with the trifunctional monoclonal antibody catumaxomab (anti-EpCAM x anti-CD3): a phase I study, #quickstatements; #temporary_batch_1590010982689) |
||
| Property / title | |||
| + | Treatment of non-small cell lung cancer patients with the trifunctional monoclonal antibody catumaxomab (anti-EpCAM x anti-CD3): a phase I study (English) | ||
| Property / title: Treatment of non-small cell lung cancer patients with the trifunctional monoclonal antibody catumaxomab (anti-EpCAM x anti-CD3): a phase I study (English) / rank | |||
| + | Normal rank | ||
Revision as of 22:04, 20 May 2020
Cited in: "Targeting cancer stem cell pathways for cancer therapy" in Signal Transduct Target Ther; 2020 ; 5 8
| Language | Label | Description | Also known as |
|---|---|---|---|
| English |
Sebastian M, et al. Cancer Immunol. Immunother. (2007) cited as Ref 561 in DOI: 10.1038/s41392-020-0110-5
|
Cited in: "Targeting cancer stem cell pathways for cancer therapy" in Signal Transduct Target Ther; 2020 ; 5 8
|
Statements
Sebastian M
0 references
2007
0 references
Cancer Immunol. Immunother.
0 references
56
0 references
Treatment of non-small cell lung cancer patients with the trifunctional monoclonal antibody catumaxomab (anti-EpCAM x anti-CD3): a phase I study (English)
0 references
